310 related articles for article (PubMed ID: 36467495)
1. Progress of oncolytic virotherapy for neuroblastoma.
Chen XT; Dai SY; Zhan Y; Yang R; Chen DQ; Li Y; Zhou EQ; Dong R
Front Pediatr; 2022; 10():1055729. PubMed ID: 36467495
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers.
Yamada T; Hamano Y; Hasegawa N; Seo E; Fukuda K; Yokoyama KK; Hyodo I; Abei M
Curr Cancer Drug Targets; 2018; 18(2):188-201. PubMed ID: 28359239
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions.
Li X; Sun X; Wang B; Li Y; Tong J
Asian J Pharm Sci; 2023 Jan; 18(1):100771. PubMed ID: 36896445
[TBL] [Abstract][Full Text] [Related]
4. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
[TBL] [Abstract][Full Text] [Related]
5. Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy.
Reale A; Calistri A; Altomonte J
Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959474
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis.
Gao P; Ding G; Wang L
Transl Cancer Res; 2021 Oct; 10(10):4290-4302. PubMed ID: 35116288
[TBL] [Abstract][Full Text] [Related]
7. Current landscape and perspective of oncolytic viruses and their combination therapies.
Su Y; Su C; Qin L
Transl Oncol; 2022 Nov; 25():101530. PubMed ID: 36095879
[TBL] [Abstract][Full Text] [Related]
8. Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers.
Scanlan H; Coffman Z; Bettencourt J; Shipley T; Bramblett DE
Front Oncol; 2022; 12():940019. PubMed ID: 35965554
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
10. The Role of Oncolytic Viruses in the Treatment of Melanoma.
Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM
Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781
[TBL] [Abstract][Full Text] [Related]
11. Review: Oncolytic virotherapy, updates and future directions.
Fountzilas C; Patel S; Mahalingam D
Oncotarget; 2017 Nov; 8(60):102617-102639. PubMed ID: 29254276
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatment.
Lee NH; Kim M; Oh SY; Kim SG; Kwon HC; Hwang TH
Oncotarget; 2017 Jan; 8(1):1213-1225. PubMed ID: 27901484
[TBL] [Abstract][Full Text] [Related]
13. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
Park SH; Breitbach CJ; Lee J; Park JO; Lim HY; Kang WK; Moon A; Mun JH; Sommermann EM; Maruri Avidal L; Patt R; Pelusio A; Burke J; Hwang TH; Kirn D; Park YS
Mol Ther; 2015 Sep; 23(9):1532-40. PubMed ID: 26073886
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic virotherapy for neuroblastoma.
Ramírez M; García-Castro J; Alemany R
Discov Med; 2010 Nov; 10(54):387-93. PubMed ID: 21122470
[TBL] [Abstract][Full Text] [Related]
15. The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594).
Breitbach CJ; Bell JC; Hwang TH; Kirn DH; Burke J
Oncolytic Virother; 2015; 4():25-31. PubMed ID: 27512667
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in oncolytic virus-based cancer therapy.
Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
[TBL] [Abstract][Full Text] [Related]
17. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
Wei D; Xu J; Liu XY; Chen ZN; Bian H
Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
[TBL] [Abstract][Full Text] [Related]
18. Immune System, Friend or Foe of Oncolytic Virotherapy?
Filley AC; Dey M
Front Oncol; 2017; 7():106. PubMed ID: 28589085
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.
Kim MK; Breitbach CJ; Moon A; Heo J; Lee YK; Cho M; Lee JW; Kim SG; Kang DH; Bell JC; Park BH; Kirn DH; Hwang TH
Sci Transl Med; 2013 May; 5(185):185ra63. PubMed ID: 23677592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
